E. Oelmann

发表

A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression

Hanif Ali, R. Sainson, A. Thotakura, 2019 .

Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma

H. Stein, H. Herbst, W. Berdel, 2015, PloS one.

Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13.

E. Thiel, A. Minty, H. Serve, 1996, Cancer research.

First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.

M. Ranson, U. Banerji, E. Harrington, 2012 .

Lymphotoxin, tumour necrosis factor and interleukin‐6 gene transcripts are present in Hodgkin and Reed‐Sternberg cells of most Hodgkin's disease cases

S. Pileri, H. Stein, B. Falini, 1993, British journal of haematology.

Autocrine interleukin‐1 receptor antagonist can support malignant growth of glioblastoma by blocking growth‐inhibiting autocrine loop of interleukin‐1

E. Thiel, H. Stein, H. Herbst, 1997, International journal of cancer.

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

W. Berdel, H. Serve, C. Müller-Tidow, 2006, Molecular Cancer Therapeutics.

Immunomagnetic selection of CD34+ cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques.

E. Thiel, C. Papadimitriou, E. Oelmann, 1995, Journal of hematotherapy.

Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma.

W. Berdel, E. Oelmann, R. Mesters, 2002, Oncology reports.

Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling.

E. Thiel, B. Wiedenmann, H. Serve, 1995, Cancer research.

Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies.

E. Thiel, H. Stein, C. Papadimitriou, 1995, Cancer research.

Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

E. Raymond, R. Kurzrock, A. Naing, 2011 .

First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

E. Raymond, R. Kurzrock, A. Naing, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines.

E. Thiel, H. Serve, C. Papadimitriou, 1995, European journal of cancer.

Megakaryocyte Growth and Development Factor Does Not Stimulate Growth of Lymphomas and Solid Tumors in vitro

W. Berdel, H. Serve, E. Oelmann, 1998, Oncology Research and Treatment.

Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma.

E. Hilgenfeld, W. Berdel, H. Serve, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Recombinant Human Interleukin 4 Has Antiproliferative Activity on Human Tumor Cell Lines Derived from Epithelial and Nonepithelial Histologies 1

E. Thiel, H. Stein, W. Berdel, 2006 .

Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism.

E. Thiel, H. Stein, Z. von Marschall, 1995, Leukemia & lymphoma.

A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.

R. Sainson, A. Thotakura, Simon J. Henderson, 2019, Journal of Clinical Oncology.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

C. Poremba, W. Berdel, E. Oelmann, 2004, Blood.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD 8 + T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets Running title : Tumor specific GvT reaction is driven by GvHD

C. Poremba, W. Berdel, E. Oelmann, 2004 .

Early Tandem High-Dose Ifosfamide, Carboplatin, Etoposide Therapy with Stem Cell Rescue for Small-Cell Lung Cancer: Brief Report on the Results of a Phase-I/II Trial

H. Serve, M. Thomas, E. Oelmann, 2002, Oncology.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

M. Ranson, U. Banerji, E. Harrington, 2015, Clinical Cancer Research.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

A. Makris, S. Kuemmel, P. Schmid, 2019, JAMA oncology.

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

E. Raymond, R. Kurzrock, G. Schwartz, 2012, British Journal of Cancer.

An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression

Hanif Ali, R. Sainson, A. Thotakura, 2020, Cancer Immunology Research.

Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells.

V. Diehl, H. Stein, H. Herbst, 2002, Blood.

A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

N. Shah, E. Harrington, B. Davies, 2018 .

Re: Leptin - A growth factor in normal and malignant breast cells and for normal mammary gland development (multiple letters) [2]

W. Berdel, H. Serve, E. Oelmann, 2003 .

Interleukin-1 receptor antagonist inhibits growth modulation of human tumor-cell lines by interleukin-1 in-vitro.

E. Thiel, C. Papadimitriou, E. Oelmann, 1994, International journal of oncology.

Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells

W. Berdel, H. Serve, T. Büchner, 2005, Annals of Hematology.